Artiva Biotherapeutics (NASDAQ:ARTV) Director Acquires $16,846.48 in Stock

Posted by George Bondi on Jul 2nd, 2026

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV – Get Free Report) Director Ra Capital Management, L.P. acquired 1,876 shares of the firm’s stock in a transaction that occurred on Friday, June 26th. The stock was purchased at an average price of $8.98 per share, with a total value of $16,846.48. Following the completion of the acquisition, the director directly owned 16,795,919 shares of the company’s stock, valued at $150,827,352.62. This represents a 0.01% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

On Thursday, June 25th, Ra Capital Management, L.P. bought 31,000 shares of Artiva Biotherapeutics stock. The shares were acquired at an average price of $8.88 per share, for a total transaction of $275,280.00.
On Tuesday, June 16th, Ra Capital Management, L.P. bought 124,893 shares of Artiva Biotherapeutics stock. The shares were acquired at an average cost of $8.89 per share, for a total transaction of $1,110,298.77.
On Monday, June 15th, Ra Capital Management, L.P. purchased 15,414 shares of Artiva Biotherapeutics stock. The stock was acquired at an average price of $8.99 per share, with a total value of $138,571.86.
On Friday, June 12th, Ra Capital Management, L.P. purchased 391,019 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $8.57 per share, with a total value of $3,351,032.83.
On Thursday, June 11th, Ra Capital Management, L.P. acquired 548,580 shares of Artiva Biotherapeutics stock. The shares were acquired at an average price of $7.91 per share, for a total transaction of $4,339,267.80.
On Wednesday, June 10th, Ra Capital Management, L.P. acquired 103 shares of Artiva Biotherapeutics stock. The shares were acquired at an average cost of $7.00 per share, for a total transaction of $721.00.
On Tuesday, June 9th, Ra Capital Management, L.P. acquired 479,039 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $6.91 per share, with a total value of $3,310,159.49.
On Monday, May 11th, Ra Capital Management, L.P. bought 6,510,416 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $11.52 per share, with a total value of $74,999,992.32.

Artiva Biotherapeutics Stock Up 1.0%

Artiva Biotherapeutics stock opened at $9.80 on Thursday. The firm has a market cap of $242.26 million, a P/E ratio of -2.77 and a beta of 2.17. The business has a fifty day moving average of $9.22 and a two-hundred day moving average of $6.72. Artiva Biotherapeutics, Inc. has a twelve month low of $1.53 and a twelve month high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) last released its quarterly earnings results on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.07). Equities analysts expect that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on ARTV. Wall Street Zen cut shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a report on Sunday, May 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Friday, April 24th. HC Wainwright increased their target price on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Wedbush raised their target price on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a research note on Monday, May 11th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, May 26th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Artiva Biotherapeutics presently has an average rating of “Moderate Buy” and an average target price of $39.00.

Get Our Latest Stock Analysis on ARTV

Institutional Investors Weigh In On Artiva Biotherapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Citadel Advisors LLC lifted its stake in Artiva Biotherapeutics by 419.3% during the 3rd quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock valued at $2,291,000 after acquiring an additional 644,658 shares during the period. BNP Paribas Financial Markets lifted its position in Artiva Biotherapeutics by 14,463.5% during the third quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock valued at $340,000 after purchasing an additional 117,733 shares during the period. Marshall Wace LLP acquired a new position in Artiva Biotherapeutics during the fourth quarter valued at $341,000. Jane Street Group LLC purchased a new stake in Artiva Biotherapeutics in the second quarter valued at $67,000. Finally, Landscape Capital Management L.L.C. acquired a new stake in Artiva Biotherapeutics during the 3rd quarter worth about $112,000.

About Artiva Biotherapeutics

(Get Free Report)

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.